If you or a loved one has developed involuntary muscle movements after taking Reglan, you may be concerned about tardive dyskinesia and how it is diagnosed. Decades of pharmacovigilance have established a clear link between metoclopramide and this movement disorder, with specific testing protocols to confirm the condition. This page covers the clinical workup and timeline for evaluation.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. Its mechanism of action, while effective for these conditions, can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by involuntary movements of the face, limbs, and trunk, and is associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan regarding the risk of TD. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, a total duration of treatment longer than 12 weeks should be avoided; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The clinical presentation of TD includes a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once present, TD tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/). While TD can affect people of all ages, older age is associated with increased risk and with the emergence of TD after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). The timeline between exposure to Reglan and documented harm can vary. A case report describes a patient who developed dyskinetic movements after intraoperative administration of a single dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This case highlights that TD can occur even after short-term exposure, though the occurrence is somewhat rare (https://pubmed.ncbi.nlm.nih.gov/34712535/). The patient in this case had several risk factors for TD, underscoring the importance of individualized risk assessment (https://pubmed.ncbi.nlm.nih.gov/34712535/).
Regarding the adequacy of warnings, the FDA has mandated a boxed warning that clearly states the risk of TD, the need for shortest duration of use, and the contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warnings and precautions section further details that Reglan can cause TD and advises immediate discontinuation if symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients, causation considerations include the duration and dosage of Reglan exposure, the presence of risk factors such as older age, and the temporal relationship between drug use and symptom onset. The boxed warning emphasizes that the risk increases with longer treatment and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, as the case report demonstrates, even a single dose can trigger TD in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/). In summary, Reglan is a known cause of tardive dyskinesia, a potentially irreversible movement disorder. The FDA has provided clear warnings about this risk, including a boxed warning and specific guidance on limiting treatment duration. Patients and healthcare providers should be vigilant for early signs of TD, especially in older adults and those with other risk factors. If symptoms develop, immediate discontinuation of Reglan is recommended.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The risk increases with longer treatment duration and higher cumulative doses, but TD can occur even after short-term exposure, as shown in a case report of a single intraoperative dose (https://pubmed.ncbi.nlm.nih.gov/34712535/).
Symptoms include involuntary movements of the face, tongue, trunk, and extremities, which can be disfiguring and persist even after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.